Navigation Links
Patient Advocate Foundation Announces Additional Support for Patient Co-Pay Relief Program Serving Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Patients
Date:6/3/2011

HAMPTON, Va., June 3, 2011/PRNewswire-USNewswire/ -- Patient Advocate Foundation (PAF) is pleased to announce that it has received a new contribution enabling it to begin offering support to patients suffering with nonsquamous non-small cell lung cancer (NSCLC) through its Co-Pay Relief Program (CPR) on June 6, 2011 at 11:00 AM EDT. PAF is a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases.

PAF's Co-Pay Relief Program provides direct financial support for pharmaceutical co-payments to insured patients, including Medicare Part D beneficiaries, who financially and medically qualify.  Since the program's inception in April 2004, CPR distributed more than $120 million in assistance to more than 46,000 patients who were unable to afford their pharmaceutical co-payments.

"A debilitating or life-threatening diagnosis can be the most overwhelming experience a person may ever face in his or her lifetime. Coupled with high-cost pharmaceutical co-pay expenses, the journey can become significantly more challenging to manage," said Nancy Davenport-Ennis, Founder and CEO of PAF. "Patient Advocate Foundation created the Co-Pay Relief Program in 2004 after receiving an increased number of patients seeking co-pay assistance for pharmaceutical drugs, so we are particularly pleased to be able to offer assistance to more patients every year."

Globally, lung cancer is the most common form of cancer and the biggest killer, causing 1.3 million cancer deaths annually.  About 85 – 90 percent of all lung cancers are NSCLC. The liver, bones and brain are potential targets if the cancerous cells enter the bloodstream. NSCLC comprises a group of histologies or tumor types differentiated by cellular structure. Nonsquamous histology includes ad
'/>"/>

SOURCE Patient Advocate Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ALTO, Calif. , July 28, 2015 ... Holding Corp., the parent company of CPI International, Inc. ... third quarter ended July 3, 2015 with the Securities ... regarding its results for the quarter.  At 11 a.m. ... a telephonic conference call in conjunction with this release ...
(Date:7/28/2015)... PARK, Calif. , July 28, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based ... announced the publication of the SENZA-RCT results in ... official Journal of the American Society of Anesthesiologists. ... a ground-breaking study that was the first to ...
(Date:7/28/2015)... 28, 2015  SeraCare Life Sciences, a leading ... today at the American Association of Clinical Chemistry ... agreement with the University of California, San Francisco ... Trisomy 18 (T18) and Trisomy 13 (T13) trophoblast ... "patient-like" reference materials for Non-Invasive Prenatal Testing (NIPT) ...
Breaking Medicine Technology:CPI International To Announce Third Quarter 2015 Financial Results 2Nevro Announces Publication of SENZA-RCT Results in Anesthesiology 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 3
... Major Lupin Limited announced today that its U.S. subsidiary, ... Award by the Healthcare Distribution Management Association (HDMA) for ... with sales of up to $100 million in the ... winners are selected by HDMA Distributor members to recognize ...
... Laboratories, a leading provider of medication monitoring services to ... hiring of Martin Price as General Counsel and Janna ... Officer. As Millennium Laboratories General Counsel, Mr. ... Howard Appel , Millennium Laboratories, President, said, "We ...
Cached Medicine Technology:HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer 2HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer 3Millennium Laboratories Announces New General Counsel Martin Price and Chief Compliance Officer Janna Sipes 2Millennium Laboratories Announces New General Counsel Martin Price and Chief Compliance Officer Janna Sipes 3
(Date:7/28/2015)... ... July 28, 2015 , ... Dr. Aziz Ahmad recently gave a talk on ... noon to 1 p.m. Tuesday, June 23, at the Gulf Coast Regional Medical Center ... is board-certified in colorectal surgery and has more than 35 years of experience in ...
(Date:7/28/2015)... ... July 28, 2015 , ... Healthpointe ’s Cosmetic Laser ... skin to a smooth state, and reduces the appearance of fine lines and wrinkles. ... FDA-approved injectable gel to instantly add volume to your cheek area to correct age-related ...
(Date:7/28/2015)... ... ... to WFTV on July 15th heroin overdose rates have increased by 270 ... statistic Orlando suffers at least one death weekly as a direct result of a ... officials are struggling to keep apace with its distribution. Officers rely on inside information ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... targeted biologics and biologic-device combination products for the treatment of bone disorders and ... U.S. Patent No. 9,062,300 entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone". ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Women fear developing ... reason is that cancer, heart attack, and stroke are treatable, but there is little ... can do is to take part in a clinical trial, reports the July 2015 ...
Breaking Medicine News(10 mins):Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3
... Cardiovascular disease (CVD) death rates are declining, but CVD ... the United States, and risk factor control remains a ... from the American Heart Associations Heart Disease and Stroke ... available in the Dec. 17 online issue of Circulation: ...
... on an enzyme that is critical to the process ... target of antibacterial and anticancer drugs. Researchers with the ... Lab) and the University of California (UC) at Berkeley ... DNA-bound Type II topoisomerase (topo II) that is responsible ...
... for Dealing With Elderly Holiday Blues Offered by One of the ... ... of the country,s senior,healthcare experts from the world-renowned Los Angeles Jewish ... group,particularly vulnerable to the blues at this time of year -- ...
... CAMPAIGN "KICK ONE, PICK ONE" ENCOURAGING ... AND SPEND TIME TOGETHER, NEW YORK, Dec. 20 ... Nite announces the launch of "Kick One, Pick One",(KOPO), the ... fit and spend more time together. Bowing Jan. 1, KOPO ...
... children , , THURSDAY, Dec. 20 (HealthDay News) -- Holiday toys ... are threatening to cause more worry than joy. , Millions ... months by toy companies, many because they were decorated with ... Barbie, and Thomas the Tank Engine, among others. , The ...
... were given Nobel Direct dental implants, the risk of the ... at the Sahlgrenska Academy in Sweden shows that eight per ... was launched in 2004 by Nobel Biocare AB. The implants ... directly into the jawbone without having to first lift up ...
Cached Medicine News:Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 2Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 3Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 4Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 5Health News:First look at an enzyme target for antibacterial and cancer drugs 2Health News:First look at an enzyme target for antibacterial and cancer drugs 3Health News:First look at an enzyme target for antibacterial and cancer drugs 4Health News:It's Not Just About the Children 2Health News:It's Not Just About the Children 3Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 2Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 3Health News:Make Safe Toys Your Holiday Priority 2Health News:Make Safe Toys Your Holiday Priority 3Health News:Gloomy forecast for Nobel Direct after 3 years 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: